Yanshole L V, Yanshole V V, Snytnikova O A, Fursova A Zh, Kolosova N G, Tsentalovich Yu P, Sagdeev R Z
International Tomography Center of the Siberian Branch of Russian Academy of the Sciences, Novosibirsk, Russia.
Novosibirsk State University, Novosibirsk, Russia.
Dokl Biochem Biophys. 2015;464:341-5. doi: 10.1134/S1607672915050191. Epub 2015 Oct 31.
The ability of SkQ1 eye drops to slow down the cataract development is demonstrated on the senescence-accelerated OXYS rats: the SkQ1 treatment leads to the considerable improvement of the lens condition as compared to the control group. The comparison of the chaperone activities of α-crystallins isolated from the rat lenses did not reveal significant difference between SkQ1-treated and control rats. The contents of major metabolites (23 compounds) in lenses of SkQ1-treated and untreated rats are also very similar, though the concentration of reduced glutathione (GSH) in lenses of SkQ1-treated rats is 12% lower. This difference may be attributed to the reduction of the oxidative stress under action of SkQ1 eye drops, and to the decreased requirement to produce high amounts of this antioxidant.
SkQ1眼药水减缓白内障发展的能力在衰老加速的OXYS大鼠身上得到了证实:与对照组相比,SkQ1治疗使晶状体状况有了显著改善。对从大鼠晶状体中分离出的α-晶状体蛋白的伴侣活性进行比较,未发现经SkQ1治疗的大鼠和对照大鼠之间存在显著差异。经SkQ1治疗和未治疗的大鼠晶状体中主要代谢物(23种化合物)的含量也非常相似,不过经SkQ1治疗的大鼠晶状体中还原型谷胱甘肽(GSH)的浓度低12%。这种差异可能归因于SkQ1眼药水作用下氧化应激的降低,以及产生大量这种抗氧化剂的需求减少。